Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06831071 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06831071 · ClinicalTrials.gov record · last posted 2026-06-10

Evaluation of Hypoxia in Primary Melanoma

StatusRecruiting
PhaseNot specified
Started2025-04-09
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
When controlling for tumor present in the Sentinel lymph node (SLN), intranodal hypoxia, as measured by Carbonic Anhydrase IX (CAIX IHC), is associated with worse PFS. This suggests that melanoma tumors may be utilizing deregulated metabolism as a means of propagating themselves to the next station of metastasis. This study aims to prospectively validate previous findings. Patients who are to undergo WLE and SLNB per standard of care (SOC) will be evaluable. It is hypothesized that SLN(s) with increased hypoxia, as measured by pimonidazole staining, will be associated with worse Progression-free Survival (PFS).

Amendment record 2 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 2 times since 2025-02-13; most recent amendment 2026-06-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-05-05
Status change Not Yet RecruitingRecruitingv1
Trial Details
NCT Number NCT06831071
Lead Sponsor Yana Najjar
Collaborators: Hypoxyprobe
Conditions Melanoma
Enrollment 50 participants
Start Date 2025-04-09
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-10